FMP
Helix BioPharma Corp.
HBP.TO
TSX
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
0.79 CAD
0 (0%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
4.24M
3.56M
3.25M
808k
1.08M
-
-
-
-
-
Total Cash %
100
100
100
100
100
100
100
100
100
Receivables
180k
353k
-
62k
54k
-
-
-
-
-
Receivables %
100
100
100
100
100
100
100
100
100
Inventories
-
-
164k
-
-
-
-
-
-
-
Inventories %
100
100
100
100
100
100
100
100
100
Payable
1.42M
1.47M
599k
493k
855k
-
-
-
-
-
Payable %
100
100
100
100
100
100
100
100
100
Cap Ex
-16k
-
-
-10k
-14k
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
